OMERACT 5 economics working group: Summary, recommendations, and research agenda

Journal of Rheumatology

Volumn 28, Issue 3, 2001, Pages 670-673

  Gabriel, S ^a   Drummond, M ^a   Coyle, D ^a   Suarez Almazor, M E ^a   Ruff, B ^a   Guillemin, F ^a   Bombardier, C ^a   Boers, M ^a   Maetzel, A ^a   Ruof, J ^a   Cranney, A ^a   Marentette, M ^a   Tugwell, P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HUMAN; ORGANIZATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REIMBURSEMENT; RHEUMATIC DISEASE; RHEUMATOLOGY; STANDARDIZATION;

COST-BENEFIT ANALYSIS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 0035092215     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Issues of consensus and debate for economic evaluation in rheumatology
2. Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses
3. Report of the OMERACT Task Force on Economic Evaluation
4. Controversies in economic evaluation in the rheumatic diseases
5. OMERACT: Economic evaluations and health policy
6. Statistical analysis of cost effectiveness data
7. The value of utility: Assumptions underlying preferences and quality adjusted life years
8. Give observational studies a chance: Better observational studies make better economic evaluations
9. Current controversies in cost effectiveness analysis of osteoporosis therapies